Thienoquinolines as novel disruptors of the PKCε/RACK2 protein-protein interaction

Journal of Medicinal Chemistry

Volumn 57, Issue 8, 2014, Pages 3235-3246

  Rechfeld, Florian ^a   Gruber, Peter ^a   Kirchmair, Johannes ^b,c   Boehler, Markus ^b   Hauser, Nina ^b   Hechenberger, Georg ^a   Garczarczyk, Dorota ^a   Lapa, Gennady B ^d   Preobrazhenskaya, Maria N ^d   Goekjian, Peter ^e   Langer, Thierry ^f   Hofmann, Johann ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c ETH ZURICH   (Switzerland)

^d GAUSE INSTITUTE OF NEW ANTIBIOTICS   (Russian Federation)

^e UNIVERSITÉ LYON 1   (France)

^f UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE C; PROTEIN KINASE C EPSILON; QUINOLINE DERIVATIVE; RACK2 PROTEIN; TRANSCRIPTION FACTOR ELK 1; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; CELL INVASION; CELL MEMBRANE; CELL MIGRATION; CELL PROLIFERATION; COMPUTER MODEL; CONTROLLED STUDY; CYTOSOL; HELA CELL LINE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELL PROLIFERATION; CHICK EMBRYO; DRUG DISCOVERY; ETS-DOMAIN PROTEIN ELK-1; HELA CELLS; HUMANS; MODELS, MOLECULAR; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN KINASE C-EPSILON; PROTEIN KINASE INHIBITORS; PROTEIN TRANSPORT; QUINOLINES; RECEPTORS, CELL SURFACE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84899497666     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401605c     Document Type: Article

References (42)

1. Gorin, M. A.; Pan, Q. Protein kinase C epsilon: an oncogene and emerging tumor biomarker Mol. Cancer 2009, 8, 9
2. Pass, J. M.; Zheng, Y.; Wead, W. B.; Zhang, J.; Li, R. C.; Bolli, R.; Ping, P. PKCepsilon activation induces dichotomous cardiac phenotypes and modulates PKCepsilon-RACK interactions and RACK expression Am. J. Physiol.: Heart Circ. Physiol. 2001, 280, H946-H955
3. Johnson, J. A.; Gray, M. O.; Chen, C. H.; Mochly-Rosen, D. A protein kinase C translocation inhibitor as an isozyme-selective antagonist of cardiac function J. Biol. Chem. 1996, 271, 24962-24966
4. Cesare, P.; Dekker, L. V.; Sardini, A.; Parker, P. J.; McNaughton, P. A. Specific involvement of PKC-epsilon in sensitization of the neuronal response to painful heat Neuron 1999, 23, 617-624
5. Castrillo, A.; Pennington, D. J.; Otto, F.; Parker, P. J.; Owen, M. J.; Boscá, L. Protein kinase Cepsilon is required for macrophage activation and defense against bacterial infection J. Exp. Med. 2001, 194, 1231-1242
6. Ikeda, Y.; Olsen, G. S.; Ziv, E.; Hansen, L. L.; Busch, A. K.; Hansen, B. F.; Shafrir, E.; Mosthaf-Seedorf, L. Cellular mechanism of nutritionally induced insulin resistance in Psammomys obesus: overexpression of protein kinase Cepsilon in skeletal muscle precedes the onset of hyperinsulinemia and hyperglycemia Diabetes 2001, 50, 584-592
7. Choi, D. S.; Wang, D.; Dadgar, J.; Chang, W. S.; Messing, R. O. Conditional rescue of protein kinase C epsilon regulates ethanol preference and hypnotic sensitivity in adult mice J. Neurosci. 2002, 22, 9905-9911
8. Akita, Y. Protein kinase Cepsilon: multiple roles in the function of, and signaling mediated by, the cytoskeleton FEBS J. 2008, 275, 3995-4004
9. Shirai, Y.; Adachi, N.; Saito, N. Protein kinase Cepsilon: function in neurons FEBS J. 2008, 275, 3988-3994
10. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the human genome Science 2002, 298, 1912-1934
11. Fedorov, O.; Marsden, B.; Pogacic, V.; Rellos, P.; Müller, S.; Bullock, A. N.; Schwaller, J.; Sundström, M.; Knapp, S. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 20523-2058
12. Nakamura, S.; Chikaraishi, Y.; Tsuruma, K.; Shimazawa, M.; Hara, H. Ruboxistaurin, a PKCbeta inhibitor, inhibits retinal neovascularization via suppression of phosphorylation of ERK1/2 and Akt Exp. Eye Res. 2010, 90, 137-145
13. Chen, Y. B.; LaCasce, A. S. Enzastaurin Expert Opin. Invest. Drugs 2008, 7, 939-944
14. Soltoff, S. P. Rottlerin: an inappropriate and ineffective inhibitor of PKCdelta Trends Pharmacol. Sci. 2007, 28, 453-458
15. Csukai, M.; Chen, C.-H.; De Matteis, M. A.; Mochly-Rosen, D. The coatomer protein b′COP: a selective protein (RACK) for epsilon protein kinase C J. Biol. Chem. 1997, 272, 29200-29206
16. Schechtman, D.; Mochly-Rosen, D. Adaptor proteins in protein kinase C-mediated signal transduction Oncogene 2001, 20, 6339-6347
17. Mochly-Rosen, D.; Khaner, H.; Lopez, J. Identification of intracellular receptor proteins for activated protein kinase C Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 3997-4000
18. Gray, M. O.; Karliner, J. S.; Mochly-Rosen, D. A selective epsilon-protein kinase C antagonist inhibits protection of cardiac myocytes from hypoxia-induced cell death J. Biol. Chem. 1997, 272, 30945-30951
19. Erdogan, E.; Lamark, T.; Stallings-Mann, M.; Jamieson, L.; Pellecchia, M.; Thompson, E. A.; Johansen, T.; Fields, A. P. Aurothiomalate inhibits transformed growth by targeting the PB1 domain of protein kinase Ciota J. Biol. Chem. 2006, 281, 28450-28459
20. Beeley, N. R. Can peptides be mimicked? Drug Discovery Today 2000, 5, 354-363
21. Arkin, M. R.; Wells, J. A. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream Nat. Rev. Drug Discovery 2004, 3, 301-317
22. Ron, D.; Jiang, Z.; Yao, L.; Vagts, A.; Diamond, I.; Gordon, A. Coordinated movement of RACK1 with activated betaIIPKC J. Biol. Chem. 1999, 274, 27039-27046
23. Brodie, C.; Bogi, K.; Acs, P.; Lazarovici, P.; Petrovics, G.; Anderson, W. B.; Blumberg, P. M. Protein kinase C plays a role in neurite outgrowth in response to epidermal growth factor and nerve growth factor in PC12 cells Cell Growth Differ. 1999, 10, 183-191
24. Fenton, R. A.; Komatsu, S.; Ikebe, M.; Shea, L. G.; Dobson, J. G., Jr. Adenoprotection of the heart involves phospholipase C-induced activation and translocation of PKC-epsilon to RACK2 in adult rat and mouse Am. J. Physiol.: Heart Circ. Physiol. 2009, 297, H718-H725
25. Xuan, Y. T.; Guo, Y.; Zhu, Y.; Wang, O. L.; Rokosh, G.; Messing, R. O.; Bolli, R. Role of the protein kinase C-epsilon-Raf-1-MEK-1/2-p44/42 MAPK signaling cascade in the activation of signal transducers and activators of transcription 1 and 3 and induction of cyclooxygenase-2 after ischemic preconditioning Circulation 2005, 112, 971-978
26. Garczarczyk, D.; Toton, E.; Biedermann, V.; Rosivatz, E.; Rechfeld, F.; Rybczynska, M.; Hofmann, J. Signal transduction of constitutively active protein kinase C epsilon Cell. Signalling 2009, 21, 745-752
27. Stensman, H.; Larsson, C. Protein kinase Cepsilon is important for migration of neuroblastoma cells BMC Cancer 2008, 8, 365
28. Gruber, P.; Rechfeld, F.; Kirchmair, J.; Hauser, N.; Boehler, M.; Garczarczyk, D.; Langer, T.; Hofmann, J. Barbituric acid derivative BAS 02104951 inhibits PKCε, PKCη, PKCε/RACK2 interaction, Elk-1 phosphorylation in HeLa and PKCε and η translocation in PC3 cells following TPA-induction J. Biochem. 2011, 149, 331-336
29. McGovern, S. L.; Helfand, B. T.; Feng, B. Y.; Shoichet, B. K. A specific mechanism of nonspecific inhibition J. Med. Chem. 2003, 46, 4265-4272
30. Rechfeld, F.; Gruber, P.; Hofmann, J.; Kirchmair, J. Modulators of protein-protein interactions-novel approaches in targeting protein kinases and other pharmaceutically relevant biomolecules Curr. Top. Med. Chem. 2011, 11, 1305-1319
31. Easmon, J.; Puerstinger, G.; Roth, T.; Fiebig, H. H.; Jenny, M.; Jaeger, W.; Heinisch, G.; Hofmann, J. 2-Benzoxazolyl and 2-benzimidazolyl hydrazones derived from 2-acetylpyridine: a novel class of antitumor agents Int. J. Cancer 2001, 94, 89-96
32. Takeishi, Y.; Ping, P.; Bolli, R.; Kirkpatrick, D. L.; Hoit, B. D.; Walsh, R. A. Transgenic overexpression of constitutively active protein kinase C epsilon causes concentric cardiac hypertrophy Circ. Res. 2000, 86, 1218-1823
33. Ferreira, J. C.; Brum, P. C.; Mochly-Rosen, D. βIIPKC and εPKC isozymes as potential pharmacological targets in cardiac hypertrophy and heart failure J. Mol. Cell. Cardiol. 2010, 51, 479-484
34. Perletti, G.; Tessitore, L.; Sesca, E.; Pani, P.; Dianzani, M. U.; Piccinini, F. Epsilon PKC acts like a marker of progressive malignancy in rat liver, but fails to enhance tumorigenesis in rat hepatoma cells in culture Biochem. Biophys. Res. Commun. 1996, 221, 688-691
35. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening J. Natl. Cancer Inst. 1990, 82, 1107-1112
36. Rao, V. N.; Huebner, K.; Isobe, M.; ar-Rushdi, A.; Croce, C. M.; Reddy, E. S. elk, tissue-specific ets-related genes on chromosomes X and 14 near translocation breakpoints Science 1989, 244, 66-70
37. Price, M. A.; Rogers, A. E.; Treisman, R. Comparative analysis of the ternary complex factors Elk-1, SAP-1a and SAP-2 (ERP/NET) EMBO J. 1995, 14, 2589-2601
38. Marais, R.; Wynne, J.; Treisman, R. The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain Cell 1993, 73, 381-393
39. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal. Biochem. 1976, 72, 248-254
40. Garczarczyk, D.; Szeker, K.; Galfi, P.; Csordas, A.; Hofmann, J. Protein kinase Cgamma in colon cancer cells: expression, Thr514 phosphorylation and sensitivity to butyrate-mediated upregulation as related to the degree of differentiation Chem.-Biol. Interact. 2010, 185, 25-32
41. Cha, D.; O'Brien, P.; O'Toole, E. A.; Woodley, D. T.; Hudson, L. G. Enhanced modulation of keratinocyte motility by transforming growth factor-alpha (TGF-alpha) relative to epidermal growth factor (EGF) J. Invest. Dermatol. 1996, 106, 590-597
42. Wolber, G.; Langer, T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters J. Chem. Inf. Model. 2005, 45, 160-169